Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer, MD

↳ This is a section part of Moment: CRT 2016 Atherosclerosis & Research - Atherosclerosis & Lipid Management

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$21.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where Are We Today? presented by H. Bryan Brewer, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$21.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physiology technicians
Nurses and other allied healthcare professionals
Imaging Specialists
Radiologists

Session Name: Atherosclerosis & Lipid Management

Track: Atherosclerosis & Research

Learning Objectives

The latest updates in Atherosclerosis & Research

Other Components in this Moment

Novel Therapies for Dyslipidemia - Michael Davidson, MD

Should We Target Triglycerides in Patients with Chronic Ischemic Heart Disease? - Allen Taylor, MD

Lipoprotein(a): Genes, Biological Role, Predictive Value and Drug Interventions - Evan Stein, MD, PhD

Update on HDL Infusions and Atherosclerosis Regression in the ACS Patient - H. Bryan Brewer, MD

What is the Role of Ezetimibe After IMPROV-IT? - Steven Nissen, MD

Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies - A. Michael Lincoff, MD

Are the PCSK9 Inhibitors the Panacea of Atherosclerosis Treatment: Effects on Lipid Lowering and Beyond - Evan Stein, MD, PhD

LDL Reduction by PCSK9 Inhibition - Steven Nissen, MD

Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer, MD

Loading Simple Education